Therapeutic and delivery strategies of phytoconstituents for renal fibrosis.
Combined administration
Delivery strategies
Phytoconstituents
Renal fibrosis
Structural modification
Journal
Advanced drug delivery reviews
ISSN: 1872-8294
Titre abrégé: Adv Drug Deliv Rev
Pays: Netherlands
ID NLM: 8710523
Informations de publication
Date de publication:
10 2021
10 2021
Historique:
received:
01
04
2021
revised:
07
07
2021
accepted:
29
07
2021
pubmed:
7
8
2021
medline:
1
2
2022
entrez:
6
8
2021
Statut:
ppublish
Résumé
Chronic kidney disease (CKD) is one of the most common diseases endangering human health and life. By 2030, 14 per 100,000 people may die from CKD. Renal fibrosis (RF) is an important intermediate link and the final pathological change during CKD progression to the terminal stage. Therefore, identifying safe and effective treatment methods for RF has become an important goal. In 2018, the World Health Organization introduced traditional Chinese medicine into its effective global medical program. Various phytoconstituents that affect the RF process have been extracted from different plants. Here, we review the potential therapeutic capabilities of active phytoconstituents in RF treatment and discuss how phytoconstituents can be structurally modified or combined with other ingredients to enhance efficiency and reduce toxicity. We also summarize phytoconstituent delivery strategies to overcome renal barriers and improve bioavailability and targeting.
Identifiants
pubmed: 34358538
pii: S0169-409X(21)00304-5
doi: 10.1016/j.addr.2021.113911
pii:
doi:
Substances chimiques
Phytochemicals
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
113911Informations de copyright
Copyright © 2021 Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: L.H. is a consultant for Samyang Biopharmaceuticals, PDS Biotechnology and Stemirna. The rest of the authors report no conflict of interest in this work..